N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

Pyxis Oncology Nasdaqpyxs Announces Earnings Results Misses Expectations by 0 02 Eps

CandidatesAnalystsFoxTumor

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Pyxis Oncology (NASDAQ: PYXS) missed earnings expectations by $0.02, causing a share price decline. The company is a clinical-stage biotech with no approved products or revenue; the earnings miss reflects R&D and G&A expenses. No direct commercial mechanism on product prices, supply chains, or margins of other firms. The impact is company-specific and limited to equity valuation.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Pyxis Oncology reported Q1 2026 EPS loss of $0.37, missing consensus by $0.02.
  • Stock fell $0.41 to $2.21 on volume over 1 million shares.
  • Market cap $138.9 million; 52-week range $0.97-$5.55.
  • Consensus rating 'Moderate Buy' with average price target $6.83.
  • Institutional ownership 39.07%.

About the publisher

tickerreport.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

tickerreport.com files this story under "candidates" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Pyxis Oncology Nasdaqpyxs Announces Earnings Results Misses Expectations by 0 02 Eps — News Analysis